Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company manufacturing and developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New triple therapy takes on pancreatic cancer Results expected Nov 2026 (estimated)
- New antibody drug aims to cut COPD attacks in half Results expected Mar 2027 (estimated)
- New hope for bile duct cancer: experimental drug targets HER2 Results expected May 2027 (estimated)
- New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials Results expected Jun 2027 (estimated)
- New pill TQH3906 tested for tough gut diseases Results expected Jul 2027 (estimated)
-
New clotting factor shows promise for hemophilia a bleeds
Disease control OngoingThis phase 3 trial tests a lab-made clotting factor VIII in 60 people with severe hemophilia A. The treatment is given on-demand for new bleeding episodes or before surgery. The goal is to see if it safely and effectively stops bleeding and supports surgical recovery.
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody drug aims to cut COPD attacks in half
Disease control OngoingThis phase 2 trial tests TQC2938, a lab-made antibody, in 256 people with moderate to severe COPD. The goal is to see if the drug can reduce the number of serious flare-ups over 24 weeks compared to a placebo. Participants receive injections and are monitored for safety and side …
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC